Genital Warts Among 18- to 59-Year-Olds in the United States, National Health and Nutrition Examination Survey, 1999–2004
- 1 April 2008
- journal article
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 35 (4) , 357-360
- https://doi.org/10.1097/olq.0b013e3181632d61
Abstract
Genital warts are caused by human papillomavirus (HPV); over 90% are due to HPV types 6 and 11. We determined the percentage of persons who reported having been diagnosed with genital warts in the United States from 1999–2004. We collected genital wart diagnosis history and sociodemographic and sexual behavior data from 8849 sexually active men and women aged 18 to 59 years as part of the National Health and Nutrition Examination Survey, 1999–2004. Overall, 5.6% of 18-to 59-year olds reported having ever been diagnosed with genital warts. The percentage was higher in women (7.2%, 95% CI, 6.2%–8.4%) than in men (4%, 95% CI, 3.2%–5.0%). History of genital wart diagnosis peaked among 25- to 34-year-old women (10.4%) and 35- to 44-year-old men (6.0%). Sex, age, race/ethnicity, number of lifetime sex partners, and cocaine/street drug use were associated with genital warts in multivariate analysis. These are the first national data on the burden of genital warts in the United States. The substantial burden of genital warts could be reduced by a prophylactic HPV vaccine to types 6 and 11.Keywords
This publication has 13 references indexed in Scilit:
- Seroepidemiology of Human Papillomavirus Type 11 in the United States: Results From the Third National Health and Nutrition Examination Survey, 1991–1994Sexually Transmitted Diseases, 2008
- High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-upBritish Journal of Cancer, 2006
- Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 diseaseVaccine, 2006
- The role of illness perceptions: psychological distress and treatment-seeking delay in patients with genital wartsInternational Journal of STD & AIDS, 2005
- Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialThe Lancet Oncology, 2005
- Assessing the Annual Economic Burden of Preventing and Treating Anogenital Human Papillomavirus-Related Disease in the USPharmacoEconomics, 2005
- Rate and Predictors of New Genital Warts Claims and Genital Warts-Related Healthcare Utilization Among Privately Insured Patients in the United StatesSexually Transmitted Diseases, 2004
- The Health and Economic Burden of Genital Warts in a Set of Private Health Plans in the United StatesClinical Infectious Diseases, 2003
- Analysis of Health SurveysPublished by Wiley ,1999
- Epidemiology of Genital Human Papillomavirus InfectionThe American Journal of Medicine, 1997